Table 3 Demographic and tumor characteristics and dose-volume factors of patients by RP status
Variables | Grade 0-1 | Grade 2 | Grade ≥ 3 | p-value |
|---|---|---|---|---|
n = 240 | n = 80 | n = 49 | ||
Sex (male/female) | 174/66 | 57/23 | 32/17 | 0.598 |
Age (≥70/<70) | 72/168 | 22/58 | 23/26 | 0.044 |
Performance status (0/1/2) | 74/157/9 | 24/55/1 | 16/32/1 | 0.808 |
Stage (IIIA/IIIB) | 159/81 | 46/34 | 29/20 | 0.299 |
Pathology (squamous/adenocarcinoma/others) | 145/81/14 | 54/23/3 | 30/15/4 | 0.723 |
CTV location | ||||
Left/right | 115/123 | 48/32 | 30/19 | 0.083 |
Upper/lower | 164/76 | 48/32 | 23/26 | 0.013 |
Smoking history (Y/N) | 153/87 | 49/31 | 28/21 | 0.668 |
Response (PR + CR/others) | 173/67 | 62/18 | 45/4 | 0.012 |
RT (3D-CRT/IMRT) | 189/51 | 63/17 | 36/13 | 0.708 |
Chemotherapy schedule (concurrent DP/concurrent NP/sequential) | 82/87/71 | 29/27/24 | 25/12/12 | 0.268 |
PTV | 396.67 ± 107.18 | 460.59 ± 105.02 | 514.92 ± 98.47 | 0.000 |
V20 | 0.28 ± 0.09 | 0.37 ± 0.09 | 0.43 ± 0.10 | 0.000 |
MLD | 14.15 ± 3.26 | 17.71 ± 3.28 | 21.40 ± 3.48 | 0.000 |
MHD | 15.24 ± 7.16 | 20.33 ± 6.36 | 22.31 ± 5.62 | 0.000 |